Elizabeth Yeu Lin - 04 Nov 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Medical Officer
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
04 Nov 2024
Net transactions value
$0
Form type
4
Filing time
06 Nov 2024, 16:40:29 UTC
Previous filing
25 Jun 2024
Next filing
07 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +41,074 $0.000000 41,074 04 Nov 2024 Common Stock 41,074 $46.21 Direct F1
transaction TARS Restricted Stock Units Award $0 +27,278 $0.000000 27,278 04 Nov 2024 Common Stock 27,278 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Option granted in connection with the Reporting Person's appointment as Chief Medical Officer as disclosed in the Form 8-K dated November 5, 2024.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 RSUs granted in connection with the Reporting Person's appointment as Chief Medical Officer as disclosed in the Form 8-K dated November 5, 2024.